If you are a member of the general public and not a healthcare professional, NOVELTY study investigator or AstraZeneca Medical employee, please CLICK HERE to see information tailored to you.

Our Mission

The NOVEL observational longiTudinal studY (NOVELTY) is a global, prospective, 3-year observational study of patients with a diagnosis or suspected diagnosis of asthma and/or COPD, with an additional 2-year extension study at participating sites. NOVELTY aims to describe patient characteristics, treatment patterns and disease burden over time across the spectrum of obstructive lung disease, providing real-world evidence to advance the development of precision medicine to deliver the right treatment to the right patient at the right time. The NOVELTY study is sponsored by AstraZeneca.

Information for the general public

NOVELTY scientific congress presence in 2022

Several NOVELTY abstracts have been presented at 2022 events.

NOVELTY treatable traits manuscript published

Now published in Respirology: Treatable traits in the NOVELTY study.

NOVELTY frequent productive cough manuscript published

Now published in Respiratory Medicine: Frequent productive cough: Symptom burden and future exacerbation risk among patients with asthma and/or COPD in the NOVELTY study.

Publications & presentations

Read summaries of publications and presentations relating to the NOVELTY study and access useful NOVELTY resources.

For investigators

Access news updates, research requests, resources and frequently asked questions relating to the NOVELTY study.

For AstraZeneca Medical employees

Access news updates, research requests, resources and frequently asked questions relating to the NOVELTY study.

19 PARTICIPATING COUNTRIES^a

~12,000 ENROLLED PATIENTS^a

84% OF PATIENTS HAVE SPIROMETRY DATA^b

You are now leaving: http://aznoveltyproject.com/

By following this link you will be leaving the NOVELTY study website.

Please note that AstraZeneca does not take responsibility for the content displayed on other websites.

Continue Return to NOVELTY study